Axsome Therapeutics (AXSM) FDA Announcement summary

Introduction and purpose

• FDA approved Symbravo (meloxicam and rizatriptan) for acute treatment of migraine with or without aura in adults, marking a significant milestone and representing a novel multi-mechanistic approach targeting multiple migraine pathways.

• Symbravo aims to address unmet needs in migraine care, targeting patients dissatisfied with current acute treatments due to limited efficacy or side effects, and is designed to provide rapid, enhanced, and consistent migraine pain relief.

• The approval provides a new option for the estimated 39 million migraine sufferers in the U.S.

Details of approval or decision

• Symbravo is indicated for acute migraine treatment in adults, with or without aura, and is not for prevention or cluster headache.

• Approval was based on pivotal phase III trials (INTERCEPT, MOMENTUM, MOVEMENT) demonstrating efficacy across mild, moderate, and severe migraine pain, covering a broad range of patient histories.

• The product uses MoSEIC technology to enhance absorption of meloxicam, combined with rizatriptan, leveraging multiple mechanisms to address both inflammation and vascular dilation.

Impact on industry and stakeholders

• Symbravo enters a large market with over 22 million annual prescriptions, mostly for generic triptans, and is positioned to compete in a concentrated market dominated by a few brands.

• Over 80% of migraine patients discontinue current treatments within a year, highlighting dissatisfaction and opportunity for new therapies.

• Market research indicates about 75% of healthcare providers are likely or extremely likely to prescribe Symbravo, citing rapid efficacy and safety.

• Patient advocacy groups highlight the approval as a step forward in reducing stigma and improving access to care.

• Symbravo is protected by patents extending to at least 2040.